Jiangsu Hengrui Medicine Co., Ltd.
600276
Kedudukan dalam Saham
#543
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Harga Saham
$6.89
Modal Pasaran
$43.94B
Perubahan (1 hari)
-2.91%
Perubahan (1 tahun)
-24.78%
Negara
CN
Perdagangan Jiangsu Hengrui Medicine Co., Ltd. (600276)
Kategori
Healthcare
Pendapatan untuk Jiangsu Hengrui Medicine Co., Ltd. (600276)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Jiangsu Hengrui Medicine Co., Ltd., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Jiangsu Hengrui Medicine Co., Ltd. dari 2001 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2025 | $1.24B | 26.71% |
| 2024 | $982.27M | 48.98% |
| 2023 | $659.33M | 14.60% |
| 2022 | $575.32M | -18.13% |
| 2021 | $702.70M | -33.43% |
| 2020 | $1.06B | 21.37% |
| 2019 | $869.67M | 32.96% |
| 2018 | $654.07M | 13.20% |
| 2017 | $577.79M | 33.13% |
| 2016 | $433.99M | 10.00% |
| 2015 | $394.53M | 35.79% |
| 2014 | $290.55M | 19.20% |
| 2013 | $243.75M | 12.88% |
| 2012 | $215.93M | 27.81% |
| 2011 | $168.94M | 29.63% |
| 2010 | $130.33M | 13.97% |
| 2009 | $114.35M | 66.01% |
| 2008 | $68.88M | -1.66% |
| 2007 | $70.05M | 89.01% |
| 2006 | $37.06M | 35.54% |
| 2005 | $27.34M | 31.05% |
| 2004 | $20.86M | 14.58% |
| 2003 | $18.21M | 36.38% |
| 2002 | $13.35M | 13.13% |
| 2001 | $11.80M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
